2026 Global: Fusion Biopsy Market -Competitive Review (2032) report
Description
The 2026 Global: Fusion Biopsy Market-Competitive Review (2032) report features the global market size and projected growth/decline data for the period 2021 and 2032. The report primarily provides an examination of the business strategies for the ten largest global companies in the market and how their strategies differ.
Major players in the fusion biopsy market include Veran Medical Technologies (St. Louis, United States), Koelis (Lyon, France), Philips Healthcare (Amsterdam, Netherlands), and Siemens Healthineers (Erlangen, Germany). Veran Medical Technologies offers the InFusion Prostate Biopsy System that integrates real-time ultrasound with MRI-derived targets to enhance lesion localization and diagnostic yield. Koelis provides the ProFuse MRI-ultrasound fusion platform and related training resources, enabling targeted prostate sampling with a user-friendly interface and 3D image fusion. Philips Healthcare supplies ultrasound systems and software capable of MRI-US fusion workflows that are widely adopted in urology clinics worldwide. Siemens Healthineers combines high-end imaging devices with fusion-enhanced guidance tools that facilitate targeted biopsies within comprehensive diagnostic suites. These four companies collectively shape standard operating procedures for image-guided biopsy, incorporating fusion algorithms, AI-assisted targeting, and cross-platform interoperability that support consistent practice and multi-center research. These developments set benchmarks for accuracy, reproducibility, and patient safety in real-world practice.
Beyond the core fusion-specialist vendors, major imaging manufacturers also contribute significantly to fusion biopsy workflows. GE Healthcare (Chicago, United States) integrates advanced ultrasound imaging with MRI fusion capabilities through its multi-modality platforms, enabling streamlined biopsy targeting across centers. Canon Medical Systems (Otawara, Japan) offers ultrasound and cross-modality fusion features embedded in its diagnostic workstations and scanners, supporting MRI- and CT-guided lesion localization. Hitachi Medical Systems (Rotkreuz, Switzerland) provides ultrasound and collaborative imaging solutions that support fusion navigation within comprehensive radiology suites, including guidance for biopsy procedures. Mindray Medical International (Shenzhen, China) supplies ultrasound systems with fusion functions that help clinicians align MRI or CT targets with live ultrasound during biopsy, broadening access in emerging markets. These entrants complement legacy MRI/US fusion platforms by expanding hardware affordability, enabling broader adoption in community hospitals and regional centers across diverse healthcare systems. Their market penetration supports education, training, and standardized protocols for patients.
Fujifilm Medical Systems, headquartered in Tokyo, Japan, offers a comprehensive imaging ecosystem that integrates diagnostic radiology, interventional suites, and ultrasound with fusion-ready software to support targeted biopsy workflows. By combining high-resolution ultrasound with MRI or CT references, Fujifilm's platforms enable clinicians to identify suspicious lesions, plan precise needle trajectories, and document biopsy targets within standardized reporting frameworks, contributing to reproducibility in multicenter studies and clinical trials. Samsung Medison, based in Seoul, South Korea, supplies advanced ultrasound systems with fusion capabilities that facilitate MRI- or CT-guided lesion localization during biopsy. Their platforms—designed for portability and clinical throughput—support real-time image registration, customizable workflows, and interoperability with hospital image databases, helping to reduce procedure times while maintaining accuracy across diverse patient populations and practice settings. Together, these two vendors contribute to broader access, standardized training, and cross-border research collaborations that inform best practices for image-guided biopsy in diverse clinical environments across global networks.
Major players in the fusion biopsy market include Veran Medical Technologies (St. Louis, United States), Koelis (Lyon, France), Philips Healthcare (Amsterdam, Netherlands), and Siemens Healthineers (Erlangen, Germany). Veran Medical Technologies offers the InFusion Prostate Biopsy System that integrates real-time ultrasound with MRI-derived targets to enhance lesion localization and diagnostic yield. Koelis provides the ProFuse MRI-ultrasound fusion platform and related training resources, enabling targeted prostate sampling with a user-friendly interface and 3D image fusion. Philips Healthcare supplies ultrasound systems and software capable of MRI-US fusion workflows that are widely adopted in urology clinics worldwide. Siemens Healthineers combines high-end imaging devices with fusion-enhanced guidance tools that facilitate targeted biopsies within comprehensive diagnostic suites. These four companies collectively shape standard operating procedures for image-guided biopsy, incorporating fusion algorithms, AI-assisted targeting, and cross-platform interoperability that support consistent practice and multi-center research. These developments set benchmarks for accuracy, reproducibility, and patient safety in real-world practice.
Beyond the core fusion-specialist vendors, major imaging manufacturers also contribute significantly to fusion biopsy workflows. GE Healthcare (Chicago, United States) integrates advanced ultrasound imaging with MRI fusion capabilities through its multi-modality platforms, enabling streamlined biopsy targeting across centers. Canon Medical Systems (Otawara, Japan) offers ultrasound and cross-modality fusion features embedded in its diagnostic workstations and scanners, supporting MRI- and CT-guided lesion localization. Hitachi Medical Systems (Rotkreuz, Switzerland) provides ultrasound and collaborative imaging solutions that support fusion navigation within comprehensive radiology suites, including guidance for biopsy procedures. Mindray Medical International (Shenzhen, China) supplies ultrasound systems with fusion functions that help clinicians align MRI or CT targets with live ultrasound during biopsy, broadening access in emerging markets. These entrants complement legacy MRI/US fusion platforms by expanding hardware affordability, enabling broader adoption in community hospitals and regional centers across diverse healthcare systems. Their market penetration supports education, training, and standardized protocols for patients.
Fujifilm Medical Systems, headquartered in Tokyo, Japan, offers a comprehensive imaging ecosystem that integrates diagnostic radiology, interventional suites, and ultrasound with fusion-ready software to support targeted biopsy workflows. By combining high-resolution ultrasound with MRI or CT references, Fujifilm's platforms enable clinicians to identify suspicious lesions, plan precise needle trajectories, and document biopsy targets within standardized reporting frameworks, contributing to reproducibility in multicenter studies and clinical trials. Samsung Medison, based in Seoul, South Korea, supplies advanced ultrasound systems with fusion capabilities that facilitate MRI- or CT-guided lesion localization during biopsy. Their platforms—designed for portability and clinical throughput—support real-time image registration, customizable workflows, and interoperability with hospital image databases, helping to reduce procedure times while maintaining accuracy across diverse patient populations and practice settings. Together, these two vendors contribute to broader access, standardized training, and cross-border research collaborations that inform best practices for image-guided biopsy in diverse clinical environments across global networks.
Table of Contents
32 Pages
- 1.0 Scope of Report and Methodology
- 2.0 Market SWOT Analysis and Players
- 2.1 Market Definition
- 2.2 Market Segments
- 2.3 Market Strengths
- 2.4 Market Weaknesses
- 2.5 Market Threats
- 2.6 Market Opportunities
- 2.7 Major Players
- 3.0 Competitive Analysis
- 3.1 Market Player 1
- 3.2 Market Player 2
- 3.3 Market Player 3
- 3.4 Market Player 4
- 3.5 Market Player 5
- 3.6 Market Player 6
- 3.7 Market Player 7
- 3.8 Market Player 8
- 3.9 Market Player 9
- 3.10 Market Player 10
- 4.0 Comparative Business Strategies
- 4.1 Comparative Business Strategies of Player 1 and 2
- 4.2 Comparative Business Strategies of Player 1 and 3
- 4.3 Comparative Business Strategies of Player 1 and 4
- 4.4 Comparative Business Strategies of Player 2 and 3
- 4.5 Comparative Business Strategies of Player 2 and 4
- 4.6 Comparative Business Strategies of Player 3 and 4
- 5.0 Appendix
Search Inside Report
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
